Workshop | Mixed
Event Title
Developing vaccines for fungal diseases: Coccidioidomycosis/Valley fever
August 13 - 14, 2024
- Date:
- August 13 - 14, 2024
- Day1:
- - ET
- Day2:
- - ET
This joint workshop between the FDA, NIH, and CDC will bring together a diverse group of stakeholders to summarize progress toward developing vaccines against fungal diseases, with an emphasis on our current understanding of the epidemiology, biology, and immunology of Valley fever; discuss current vaccine programs, essential diagnostics, and regulatory pathways; and identify remaining gaps and opportunities to support the successful development of a vaccine against Valley Fever and other fungal infections.
Valley fever, also called coccidioidomycosis, is one of the most common endemic fungal infections in the United States with over 20,000 cases reported to the CDC annually and over 200,000 estimated symptomatic infections. Due to similarities with other respiratory illnesses and nonspecific symptoms, Valley fever is often misdiagnosed. The course of infection may be self-limited, but in some cases, Valley fever can affect previously healthy individuals, cause severe or life-threatening illness, and require prolonged antifungal therapy. Natural infection confers protection against future disease, suggesting that a vaccine is possible. Several vaccine strategies and platforms are in early stages of development, but more research and support are needed to realize the goal of a Valley fever vaccine.
Registration and other event details can be found at https://web.cvent.com/event/1144a908-0d15-4b26-8ca5-503ca80962c4/summary
Event Materials
| Title | File Type/Size |
|---|---|
| Draft Agenda - Developing vaccines for fungal diseases: Coccidioidomycosis/Valley fever Workshop | pdf (295.57 KB) |